ID   DM400
AC   CVCL_ZL78
SY   Duke Melanoma 400
DR   Wikidata; Q98125895
RX   PubMed=9241074;
RX   PubMed=11520076;
CC   From: Duke University Medical Center; Durham; USA.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 14-08-25; Version: 4
//
RX   PubMed=9241074; DOI=10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO;2-U;
RA   Abdel-Wahab, Zeinab
RA   Weltz, Christina
RA   Hester, Dina
RA   Pickett, Nancy
RA   Vervaert, Carol
RA   Barber, Jack R.
RA   Jolly, Douglas J.
RA   Seigler, Hilliard Foster
RT   "A phase I clinical trial of immunotherapy with interferon-gamma
RT   gene-modified autologous melanoma cells: monitoring the humoral immune
RT   response.";
RL   Cancer 80:401-412(1997).
//
RX   PubMed=11520076; DOI=10.1006/cimm.2001.1809;
RA   Zennadi, Rahima
RA   Abdel-Wahab, Zeinab
RA   Seigler, Hilliard Foster
RA   Darrow, Timothy L.
RT   "Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells:
RT   requirement of both HLA-DR15 and Fas antigens on melanomas for their
RT   lysis by Th2 cells.";
RL   Cell. Immunol. 210:96-105(2001).
//